Consumer medicine information

Minirin Nasal Drops Nasal drops

Desmopressin acetate

BRAND INFORMATION

Brand name

Minirin Nasal Drops

Active ingredient

Desmopressin acetate

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Minirin Nasal Drops Nasal drops.

What is in this leaflet

This leaflet answers some common questions about MINIRIN Nasal Drops. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you using MINIRIN Nasal Drops against the benefits they expect it will have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Keep this leaflet with the medicine. You may need to read it again.

What MINIRIN Nasal Drops is used for

The active ingredient, desmopressin acetate, in MINIRIN Nasal Drops is a synthetic version of a naturally occurring substance produced in the brain called vasopressin.

It has a number of different actions on the body including an action on the kidney to reduce the amount of urine produced. This means that MINIRIN Nasal Drops can be used for several of different conditions including:

  • cranial diabetes insipidus (large amounts of urine being produced day and night and constant thirst)
  • as a diagnostic test to establish if the kidneys have the ability to concentrate urine.

Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed it for another reason.

This medicine is not addictive.

It is available only with a doctor's prescription.

This medicine is not expected to affect your ability to drive a car or operate machinery.

Before you use MINIRIN Nasal Drops

When you must not use it

Do not use MINIRIN Nasal Drops if you have an allergy to:

  • any medicine containing desmopressin or any of the ingredients listed at the end of this leaflet.

Some of the symptoms of an allergic reaction may include:

  • shortness of breath, wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives on the skin.

Do not use MINIRIN Nasal Drops if you:

  • suffer from polydipsia (excessive thirst and increased fluid intake) or psychogenic polydipsia (psychologically - caused increased thirst and increased fluid intake) or where you are in the habit of drinking large amounts of fluid
  • have cardiac insufficiency (heart failure in which the heart is not able to pump enough blood throughout the body resulting in shortness of breath, swelling of the feet or legs due to fluid build-up)
  • you are taking diuretics (water or fluid tablets)
  • have moderately or severely reduced kidney function where you pass little or no urine
  • have low levels of sodium in your blood have SIADH (hormone secretion disorder where there is an overproduction of a hormone causing fluid retention, resulting in weakness, tiredness or confusion).

Do not breast-feed if you are using this medicine. MINIRIN Nasal Drops is not recommended while you are breast-feeding.

Do not give this medicine to a child under the age of 6 years. Safety and effectiveness in children younger than 6 years have not been established.

Do not use this medicine after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering. If it has expired or is damaged, return it to your pharmacist for disposal.

MINIRIN Nasal Drops should only be used when oral forms of MINIRIN are inappropriate. This is because a side-effect that can change the fluid and salt balance in your body is less common with oral forms. For further information, please discuss this with your doctor.

If you are not sure whether you should start using this medicine, talk to your doctor.

Before you start to use it

Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.

Tell your doctor if you have or have had any of the following medical conditions:

  • a known allergy to anti-diuretic hormone (ADH)
  • too little or too much fluid in the body
  • currently have a nasal infection or blocked up or runny nose
  • heart or blood vessel disease or any other disease for which you take diuretics
  • low blood pressure
  • cystic fibrosis or any other disease which causes fluid or salt imbalance
  • any disease of the blood clotting cells (platelets)
  • serious problems with bladder function or with passing urine.

Tell your doctor if you are pregnant or plan to become pregnant or are breast-feeding.

MINIRIN Nasal Drops should only be used in a pregnant woman if necessary. Your doctor can discuss with you the risks and benefits involved.

Do not breast-feed if you are using this medicine. The active ingredient in MINIRIN Nasal Drops passes into breast milk. Therefore this medicine is not recommended while you are breast-feeding.

If you have not told your doctor about any of the above, tell him/her before you start using MINIRIN Nasal Drops.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop.

Some medicines and MINIRIN Nasal Drops may interfere with each other. These include:

  • tricyclic antidepressants, which are medicines used to treat e.g. depression (such as clomipramine, imipramine, desipramine)
  • selective serotonin reuptake inhibitors (SSRIs), which are medicines used to treat e.g. depression or anxiety (such as citalopram, paroxetine, sertraline)
  • chlorpromazine, which is an anti-psychotic medicinal product used to treat e.g. schizophrenia
  • carbamazepine, which is used to treat e.g. bipolar disorder and epilepsy
  • antidiabetic medicinal products used for type II diabetes (medicines in the sulfonylurea group), particularly chlorpropamide
  • medicines used to treat high blood pressure and some other conditions (ACE inhibitors or angiotensin receptor blockers e.g. enalapril, perindopril, irbesartan etc.)
  • non-steroidal anti-inflammatory drugs (NSAIDs), which are medicinal products used for the treatment of pain and inflammation (e.g. aspirin and ibuprofen).

These medicines may be affected by MINIRIN Nasal Drops or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.

Your doctor and pharmacist have more information on medicines to be careful with or avoid while using this medicine.

How to use MINIRIN Nasal Drops

Follow all directions given to you by your doctor or pharmacist carefully. They may differ from the information contained in this leaflet.

The instructions on how to use MINIRIN Nasal Drops are included in the carton.

It is very important for you to follow these instructions closely to make sure that you will always receive the correct dose of your medication. MINIRIN Nasal Drops is meant to be administered into the nostrils.

The required dose should be loaded from the dropper bottle into the plastic tube (rhinyle) according to the detailed instructions for use in the pack.

One end of the plastic tube is placed into the mouth and the other end into a nostril and the contents of the plastic tube are blown into the nasal cavity. Do not inhale (sniff the solution).

If you do not understand the instructions in the leaflet, ask your doctor or pharmacist for help.

How much to use

Some of the details for MINIRIN Nasal Drops will vary depending on the purpose for which it is used.

Cranial diabetes insipidus
The dose you need will be adjusted to suit your personal requirements. MINIRIN Nasal Drops may be given in one or two divided doses each day. The daily dose is usually given as two divided doses. Sometimes a single daily dose is sufficient to control your condition. The average daily dose for adults is 0.1 mL to 0.4 mL (10 micrograms to 40 micrograms). The dose for children will vary between 0.025 mL and 0.2 mL (2.5 micrograms to 20 micrograms).

Test the ability of the kidneys to concentrate urine
If you are an adult, you will require a single dose of up to 40 micrograms at any one time.

If you are a child, you will require a single dose of up to 20 micrograms at any one time.

Children who are less than one year of age and need to be tested for the ability of the kidney to concentrate urine should require a single dose of up to 10 micrograms and under careful supervision in hospital.

When to use it

Cranial diabetes insipidus

  • use MINIRIN Nasal Drops at times specified by your doctor.

Test the ability of the kidneys to concentrate urine

  • Your doctor will advise you.

How long to use it

Cranial diabetes insipidus
It is likely that you will need to use MINIRIN Nasal Drops or other forms of MINIRIN for the rest of your life.

This medicine helps to control your condition, but does not cure it. It is important to keep using your medicine even if you feel well.

MINIRIN Nasal Drops can prevent or control the thirst and frequent urination associated with cranial diabetes insipidus. You will be less thirsty and urinate a smaller volume less often.

Test the ability of the kidneys to concentrate urine
Your doctor will advise you.

If a dose is missed

Cranial diabetes insipidus
Take the next dose as soon as you remember. You will then have to adjust the time of the following dose.

When this is done, go back to using your medicine as you would normally. You should talk to your doctor about this situation. Do not take a double dose.

If you are not sure what to do, ask your doctor or pharmacist.

If you have trouble remembering to take your medicine, ask your pharmacist for some hints.

If you use too much (overdose)

Immediately telephone your doctor or the Poisons Information Centre (telephone 13 11 26) for advice, or go to Accident and Emergency at the nearest hospital, if you think that you or anyone else may have used too much MINIRIN Nasal Drops. Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.

Symptoms of an overdose may include confusion, drowsiness, continuing headache, nausea or vomiting, rapid weight gain due to a build-up of water in the body, or, in severe cases, convulsions.

While you are using MINIRIN Nasal Drops

Things you must do

If you are about to be started on any new medicine, remind your doctor and pharmacist that you are using MINIRIN Nasal Drops.

Tell any other doctors, dentists, and pharmacists who treat you that you are using this medicine.

If you are going to have surgery, tell the surgeon or anaesthetist that you are using this medicine. It may affect other medicines used during surgery.

If you become pregnant while using this medicine, tell your doctor immediately.

If you are about to have any blood tests, tell your doctor that you are using this medicine. It may interfere with the results of some tests.

Keep all of your doctor’s appointments so that your progress can be checked. Your doctor may do some tests from time to time to make sure the medicine is working and to prevent unwanted side effects.

Things you must not do

Do not use MINIRIN Nasal Drops to treat any other complaints unless your doctor tells you to do so.

Do not give your medicine to anyone else, even if they have the same condition as you.

Do not stop using your medicine or change the dosage without checking with your doctor. If you stop using it suddenly, your condition may worsen.

Things to be careful of

All patients on treatment with this medicine should avoid excessive fluid intake as this may lead to a build-up of water in the body.

Cranial diabetes insipidus

Carefully follow your doctor’s instruction about fluid intake. It is very important to keep your body water in balance, so that you do not let yourself get too thirsty or drink too much fluid.

Test the ability of the kidneys to concentrate urine

You must limit fluid intake and not exceed 500 mL of fluid from one hour before using MINIRIN Nasal Drops until at least eight hours after administration of the spray. This is because a high fluid intake during this period can increase the chance that you will feel unwell (e.g. headache, nausea, dizziness).

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are using MINIRIN Nasal Drops.

This medicine helps most people but it may have unwanted side effects in a few people. All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects.

If you are over 60 years of age you may have an increased chance of getting side effects.

Do not be alarmed by the following lists of side effects. You may not experience any of them.

Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor or pharmacist if you notice any of the following and they worry you:

  • nasal congestion
  • runny or blocked nose, sneezing, facial pressure or pain
  • increased body temperature (fever)
  • trouble sleeping
  • nightmare
  • nervousness
  • headache
  • nose bleed
  • upper respiratory tract infection
  • inflammation of the stomach and intestines
  • stomach pain or nausea.

The above list includes the more common side effects of your medicine. They are usually mild and short-lived.

Tell your doctor as soon as possible if you notice any of the following:

  • emotional, behavioural or visual disturbances
  • allergic reactions including skin rash or more general reactions.

The above list includes serious side effects which may require medical attention. Serious side effects are rare.

If you notice any of the following, tell your doctor immediately or go to Accident and Emergency at your nearest hospital:

  • confusion or drowsiness
  • continuing headache
  • nausea or vomiting
  • rapid weight gain, which may be due to a build-up of water in the body
  • convulsions, fitting and blackouts.

The above list includes very serious side effects. You may need urgent medical attention or hospitalisation. These side effects are very rare.

Tell your doctor or pharmacist if you notice anything that is making you feel unwell.

Other side effects not listed above may also occur in some people.

After using MINIRIN Nasal Drops

Storage

Keep MINIRIN Nasal Drops in a refrigerator at a temperature between 2°C and 8 °C. Do not freeze. Keep it in its original packaging and protect it from light. If you store the medicine out of its original packaging it may not keep well.

Do not store MINIRIN Nasal Drops, or any other medicine, in the bathroom or near a sink. Do not leave it on a window sill or in the car. Heat and dampness can destroy some medicines.

Keep it where children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Disposal

If your doctor tells you to stop using this medicine or the expiry date has passed, ask your pharmacist what to do with any medicine that is left over.

Product description

What it looks like

MINIRIN Nasal Drops is supplied in a brown dropper bottle of 2.5 mL containing 100 micrograms/mL of desmopressin acetate. A graduated plastic tube (rhinyle) is also included.

Ingredients

MINIRIN Nasal Drops contains 100 micrograms/mL of the active ingredient, desmopressin acetate (DDAVP).

It also contains:

  • chlorobutanol hemihydrate as a preservative
  • sodium chloride
  • hydrochloric acid to adjust the pH
  • purified water.

This medicine does not contain sucrose, gluten, tartrazine or any other azo dyes.

Sponsor

MINIRIN Nasal Drops is supplied in Australia by:

Ferring Pharmaceuticals Pty Ltd
Suite 2, Level 1, Building 1
20 Bridge Street
Pymble, NSW 2073
Australia.

AUST R 16828 - MINIRIN desmopressin acetate 0.1 mg/mL nasal drops bottle

This leaflet was prepared in December 2018.

#156-v4A

MINIRIN and FERRING are registered trademarks of Ferring B.V.

Published by MIMS February 2019

BRAND INFORMATION

Brand name

Minirin Nasal Drops

Active ingredient

Desmopressin acetate

Schedule

S4

 

1 Name of Medicine

Desmopressin acetate.

2 Qualitative and Quantitative Composition

Minirin Nasal Drops contain desmopressin 100 micrograms/mL.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Nasal Drops, solution.

4 Clinical Particulars

4.1 Therapeutic Indications

Diabetes insipidus.

The treatment of ADH-sensitive cranial diabetes insipidus, including treatment of post-hypophysectomy polydipsia and polyuria.

Renal concentrating capacity.

As a diagnostic test to establish renal concentrating capacity.

4.2 Dose and Method of Administration

a. For ADH-sensitive cranial diabetes insipidus.

Adult.

The average daily dose is 10 to 40 micrograms intranasally.

Paediatric.

2.5 to 20 micrograms daily.
The daily dose is usually given as two divided doses separately adjusted if necessary. The dosage must be determined for each individual patient and adjusted according to the diurnal pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, but not excessive, water turnover. In the event of signs of water retention/hyponatraemia, treatment should be interrupted and the dose adjusted. A single daily dose may be appropriate if it is tolerated and also satisfactorily controls the diabetes insipidus. About one third of patients may be controlled on a small daily dose. For immediate postoperative polyuria and polydipsia, the dose should be controlled by measurement of the urine osmolality. Monitoring in a high dependency setting is recommended. If there is doubt that a dose has been administered, a second dose should not be given until diuresis has occurred.

Mode of administration.

The required dose is first loaded from the dropper bottle into the plastic catheter following the manufacturer's detailed instructions. One end of the catheter is then placed into the mouth and the other end into a nostril; and the content of the catheter is blown into the nasal cavity.

b. As a diagnostic test of renal concentrating capacity.

(See Section 4.4 Special Warnings and Precautions for Use, In addition for renal concentrating capacity testing.)

Adults.

Single dose of up to 40 micrograms.

Children.

Single dose of up to 20 micrograms.

Infants.

Single dose of up to 10 micrograms.

Instructions to be given to patients.

Patient using intranasal desmopressin acetate for the first time should be adequately instructed by their physician to ensure that the dose is correct. Patients should be warned not to inhale the drug.
Physicians should base their instruction on the manufacturer's patient leaflet, which also gives information on cleaning the catheter and storing the solution.

4.3 Contraindications

Habitual and psychogenic polydipsia (resulting in a urine production exceeding 40 mL/kg/24 hours).
A history of known or suspected cardiac insufficiency and other conditions requiring treatment with diuretics.
Moderate and severe renal insufficiency (creatinine clearance below 50 mL/min).
Known hyponatraemia.
Syndrome of inappropriate anti-diuretic hormone secretion (SIADH).
Hypersensitivity to desmopressin acetate or any of the excipients.

4.4 Special Warnings and Precautions for Use

Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus.
Minirin Nasal Drops should only be used in patients where orally administered formulations are not feasible.
It is recommended to start at the lowest dose, ensure compliance with fluid restriction instructions, and increase dose progressively, with caution. Patient dosage should be reassessed periodically. Ensure adult supervision when a child is administering the drug in order to control the dose intake.
All patients and, when applicable, their guardians should be carefully instructed to adhere to the fluid restrictions.

In addition for central diabetes insipidus.

The aim of fluid therapy is to replace urinary fluid loss.
Children, patients with cognitive impairment, and patients with inadequate thirst sensation need close monitoring of fluid intake.
Regular monitoring of serum and urinary sodium and osmolality is recommended at the discretion of the clinician.

In addition for renal concentrating capacity testing.

When used for diagnostic purposes the fluid intake must be limited to a maximum of 0.5 L to satisfy thirst from 1 hour before until at least 8 hours after administration. Renal concentrating capacity testing in children below the age of 1 year should only be performed under carefully supervised conditions in hospital.
Severe bladder dysfunction and outlet obstruction should be considered before starting treatment.
Infants, elderly and patients with serum sodium levels in the lower range of normal may have an increased risk of hyponatraemia. Treatment with desmopressin should be interrupted or carefully adjusted during acute intercurrent illnesses characterised by fluid and/or electrolyte imbalance (such as systemic infections, fever, gastroenteritis).
Used with caution in patients at risk for increased intracranial pressure; and in patients with conditions characterised by fluid and/or electrolyte imbalance.
Desmopressin acetate should not be administered to dehydrated or overhydrated patients until water balance has been adequately restored. Fluid intake should be restricted as much as possible and the patient should be weighed regularly.

Hyponatraemia and hydration.

Hyponatraemia in the context of the use of desmopressin is generally due to fluid overload, thus careful attention to fluid balance is needed. Other causes of hyponatraemia which may need excluding depending on the clinical situation include renal salt wasting due to central lesions, renal disorders or adrenal disorders.

Myocardial ischaemia.

Desmopressin acetate should be used with caution in patients with cardiovascular disease and the elderly.

Hypersensitivity.

Patients with a known hypersensitivity to ADH, should be tested for sensitivity to desmopressin acetate before the full dose is given.

Post-operative use.

The use of desmopressin in a post-operative setting should only occur after the diagnosis of diabetes insipidus has been confirmed. Small doses should be administered with strict fluid balance and regular clinical assessment.

In patients with platelet dysfunction.

Skin bleeding time should be monitored: i. before surgery with marked prolongation indicating high risk of increased blood loss; ii. during treatment with desmopressin acetate.
Minirin should be used with caution in patients with cystic fibrosis because of impaired water handling and increased risk of hyponatraemia.

Nasal infections/rhinorrhoea.

Intranasal administration may be ineffective in the presence of local infection or rhinorrhoea.

4.5 Interactions with Other Medicines and Other Forms of Interactions

See Table 1.
It is unlikely that desmopressin will interact with drugs affecting hepatic metabolism, since desmopressin has been shown not to undergo significant liver metabolism in in vitro studies with human microsomes. However, formal in vivo interaction studies have not been performed.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
(Category B1)
Caution should be exercised when prescribing to pregnant women.
Data on a limited number (n=53) of exposed pregnancies in women with diabetes insipidus as well as data on a limited number of exposed pregnancies in women with bleeding complications (n=216) indicate no adverse effects of desmopressin on pregnancy or on the health of the fetus/newborn child. To date, no other relevant epidemiological data are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/fetal development, parturition or postnatal development.
Embryofetal development studies performed with desmopressin in rats and rabbits given subcutaneous doses up to 50 nanogram/kg/day and 200 microgram/kg/day, respectively, and in rats given intravenous doses up to 241 microgram/kg/day, revealed no evidence for a harmful effect on the fetus.
Subtherapeutic levels of desmopressin acetate have been detected in the breast milk of lactating women. Until further evidence of its safe use during lactation is available, it is not to be administered to lactating women.

4.7 Effects on Ability to Drive and Use Machines

Minirin Nasal Drops has no or negligible influence on the ability to drive and use machines.

4.8 Adverse Effects (Undesirable Effects)

Table 2 is based on the frequency of adverse reactions reported with Minirin Nasal Drops conducted in children and adults.

Post marketing experience.

Table 3 lists additional adverse drug reactions reported in the post marketing period in children, adolescents and adults treated with desmopressin, distributed by organ class. The frequency of adverse drug reactions occurring in the post marketing period is regarded as unknown.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

Overdose of Minirin Nasal Drops leads to a prolonged duration of action with an increased risk of water retention and hyponatraemia.

Treatment.

Treatment of hyponatraemia should be individualised. Treatment should include discontinuing desmopressin, instigation of fluid restriction and symptomatic treatment if needed.
For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: vasopressin and analogues.
ATC code: H01B A02.
Minirin Nasal Drops contain desmopressin, a structural analogue of the natural pituitary hormone arginine vasopressin, also known as antidiuretic hormone (ADH). Early treatment of central diabetes insipidus used a more or less purified extract from bovine or porcine posterior pituitaries. These caused unpleasant complications of use. When vasopressin became known, two forms were found - arginine vasopressin (found in humans) and lysine vasopressin (found in pig pituitaries).
Two chemical changes have been made to the natural hormone to form desmopressin:
a. desamination of the N-terminal of cysteine-1;
b. substitution of 8-D-arginine for 8-L-arginine.
According to results from antidiuretic and pressor tests in rats these changes increase antidiuretic activity three to five fold, while pressor activity is reduced to 0.1% of that of ADH.

Mechanism of action.

The actions of Minirin Nasal Drops can be summarised as follows:

Antidiuretic action.

Minirin acts at a receptor site in the renal collecting tubule to increase permeability to water reabsorption.

Other effects.

Oxytocic effect.

A slight in vitro oxytocic effect has been reported in animals. A slight stimulatory effect on uterine activity in non-pregnant women has been noted at doses of 15 and 20 micrograms intranasally (see Section 4.6 Fertility, Pregnancy and Lactation, Use in pregnancy).

5.2 Pharmacokinetic Properties

Absorption.

Used intranasally, it is estimated that 10% is available.

Distribution.

It is believed to be similar to ADH. No information is available on protein binding.

Metabolism.

It is thought that the presence of the D-isomer in position eight protects desmopressin from the enzyme which inactivates ADH.

Excretion.

The excretion of desmopressin is similar to that of ADH but considerably slower. Clinically intranasal desmopressin is effective for approximately 10-12 hours.

Half-life.

No information is available for intranasal administration. After i.v administration of labelled desmopressin, biexponential half-lives of 7.8 minutes and 75.5 minutes were recorded. The duration of drug effect is 8-20 hours, with much individual variation.

Clinical implications of pharmacokinetic data.

Desmopressin is thought to be resistant to the inactivation that occurs with ADH. Intravenous or intramuscular doses should be about one tenth the intranasal dose for equivalent efficacy.
In some patients, the duration of effect may be sufficiently long to permit once daily dosage if the single dose can be tolerated.

5.3 Preclinical Safety Data

Genotoxicity.

No data available.

Carcinogenicity.

No data available.

6 Pharmaceutical Particulars

6.1 List of Excipients

Minirin Nasal Drops contains sodium chloride, hydrochloric acid and purified water. It also contains chlorobutanol hemihydrate as preservative.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store at 2 to 8°C. Refrigerate. Do not freeze. Protect from light.

6.5 Nature and Contents of Container

Minirin Nasal Drops: Dropper bottles of 2.5 mL supplied with plastic rhinyle (catheter).

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Synonyms of desmopressin.

DDAVP.
1-desamino-8-D-Arginine vasopressin.
Desamino-cys- 1-D-Arginine-8-vasopressin.

Molecular weights.

Desmopressin base: 1069.22.
Desmopressin acetate: 1183.34.
Desmopressin is a white, fluffy powder, soluble in water, alcohol and glacial acetic acid.

Chemical structure.


CAS numbers.

Desmopressin base: 16679-58-6.
Desmopressin acetate: 62288-83-9.

7 Medicine Schedule (Poisons Standard)

S4.

Summary Table of Changes